Vertex Moves to Expand Into Rare Hormonal Diseases With $10 Billion Crinetics Deal
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion, expanding its business beyond its established focus on cystic fibrosis and into rare endocrine diseases. Under the agreement, Vertex will pay $85 per Crinetics share, representing a premium of approximately 102% to Crinetics’ share price before the deal was announced. The transaction is […]
Continue Reading